The events were reported through a retrospective clinical trial.Btg medical assessment: patient is a subject enrolled in the (b)(6) study: male (b)(6), white, hcc diagnosed (b)(6) 2015 with radiology, one nodule in segment viii, albumin 30g/l, afp 1835 ng/ml, child a6 bclc a.First therasphere® administration (b)(6) 2015: patient was diagnosed with sepsis (b)(6) 2015 and (approximately 10 days after treatment)approximately 10 days after treatment, he was admitted to an outside hospital in (b)(6) for fatigue, weakness and concern over infection with sirs physiology.He received a course of antibiotics and was discharged with a home nurse as well as occupational therapy.At the follow up visit (b)(6) 2016, hematology tests were within the limits of normal an afp has decrease to 21 ng/ml.Conclusion: syndrome that combines fatigue and fever, in accordance with diagnosis of systemic inflammatory response syndrome (sirs).This is an inflammatory state affecting the whole body in response to an infectious or non infectious insult.Antibiotics were provided, however the occurrence of an infection was not documented, event = sirs + proven of probable infection = sepsis, severity grade 3, serious ae, which lead to hospitalization and medical intervention, anticipated ae, related to therasphere® administration.No device malfunction was reported and no corrective and preventive action (capa) plan has been identified.The lot number associated with the therasphere administration was not reported, therefore no investigation could be performed.If additional information becomes available, a follow up report will be submitted.No other information is available that could confirm/deny the alleged event.Sepsis is an anticipated adverse event as per the ifu/risk management documentation.At this time this report is considered final.
|
Subject (b)(6) is an (b)(6) white male patient enrolled in the (b)(6) study.Medical history of: alcohol abuse; cirrhosis; diabetes; (b)(6); smoker; other - fissure anal; barret oesophagus; meningitis; arthritis.Hcc diagnosed on (b)(6) 2015, one nodule in segment viii, therasphere® administered (b)(6) 2015, total administered activity gbq 1.8572, lung shunt fraction 7.54%.Patient was diagnosed with sepsis (b)(6) 2015 and (approximately 10 days after treatment) patient was admitted to an outside hospital in for fatigue, weakness and concern over infection with sirs physiology.He received a course of antibiotics and was discharged with a home nurse as well as occupational therapy.He tells me that he suffered severe fatigue, which has improved but certainly not resolved by today.Patient was discharged (b)(6) 2015.Outcome: resolved.The events were not reported to btg by the investigator in 2015.
|